Tailoring Therapy to Older Patients with Acute Myeloid Leukemia
Please complete Pre-test
Chapter 1 of 2
Release Date: September 14, 2017
Expiration Date: September 14, 2018
Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.
Acute myeloid leukemia (AML) is generally a hematologic malignancy of older adults, with approximately 60% of newly diagnosed AML patients being 60 or older. Older patients pose unique therapeutic challenges that have been largely unmet to date. This activity will review and discuss decision-making strategies outlining when and how to treat this patient population in your practice. In addition, Dr. Nazha will provide an overview of the current treatment paradigms available, as well as agents currently approved or under investigation which may have a potential role in the outcome of the older patient with AML.
This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Describe assessment and testing strategies that may influence treatment decisions in older patients with acute myeloid leukemia (AML)
- Summarize the optimal therapeutic approach based on individual patient needs, physical status, and quality of life
- Relate how new and targeted therapies currently approved or in clinical trials may impact and/or improve the current treatment paradigm in the older patient with AML
Tailoring Therapy to Older Patients with Acute Myeloid Leukemia – Aziz Nazha, MD
Instructions for Participation and Credit
This activity is eligible for credit through September 14, 2018. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Aziz Nazha, MD
Assistant Professor, Lerner College of Medicine
Associate Staff, Taussig Cancer Institute
Dr. Aziz Nazha received his medical degree from Tishreen University in Syria, and continued his post-graduate training as a resident in internal medicine at Thomas Jefferson University Affiliated, Atlanticare Regional Medical Center. He also completed a leukemia fellowship at The University of Texas, MD Anderson Cancer Center, and a hematology and medical oncology fellowship at Cleveland Clinic, Taussig Cancer Institute. Dr. Nazha is an Assistant Professor at Lerner College of Medicine and an Associate Staff Member at Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Dr. Nazha is board certified by the American Board of Internal Medicine, American Board of Hematology, and the American Board of Medical Oncology. He holds memberships in the American Society of Clinical Oncology, American Society of Hematology, Society of Hematologic Oncology, American Medical Association, American College of Physicians, and the American Association of Cancer Research. Dr. Nazha is on the editorial boards of Annals of Hematology & Oncology, Annals of Clinical Case Reports, Journal of Blood Disorders and Therapy, Cancer Biology & Medicine, and Cancer Treatment and Research Communications. In addition, he is an ad hoc reviewer for the Journal of Clinical Oncology, Clinical Lymphoma, Myeloma & Leukemia, Journal of Graduate Medical Education, Journal of Blood Disorders and Therapy, Haematologica, Leukemia, Research, JAMA Oncology, Cancer Science, American Journal of Hematology, Journal of Leukocyte Biology, Leukemia & Lymphoma, and Leukemia. He has written and published more than 50
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Agios Pharmaceuticals, Celgene Corporation, Helsinn, Incyte Corporation, Jazz Pharmaceuticals, Inc., and Novartis Pharmaceuticals.
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-165-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Aziz Nazha has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.